Oct 2 (Reuters) – Chinese biotech company Abogen said on Friday it signed a licensing deal worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy. Novartis will gain
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)